Traussnigg S, Kienbacher C, Gajdošík M, et al. Ultra‐high‐field magnetic resonance spectroscopy in non‐alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non‐alcoholic steatohepatitis and advanced fibrosis. Liver Int. 2017;37:1544‐1553. <https://doi.org/10.1111/liv.13451> 28544208

**Funding information**

The research leading to these results has been partly funded by the European Union Seventh Framework Programme (/FP7/2007‐2013)/UNDER/GRANT AGREEMENT/N° HEALTH‐F2‐2009‐241762, for the project FLIP, grant F3008‐B05 from the Austrian Science Foundation (FWF) and grant LS12‐008 from the Vienna Science and Technology Fund

Handling Editor: Luca Valenti

ATP

:   adenosine triphosphate

BMI

:   body mass index

CSI

:   chemical shift imaging

ER

:   endoplasmic reticulum

FA

:   fatty acid

F~ATP~

:   forward exchange flux

FOV

:   field of view

GPC

:   glycerophosphocholine

GPE

:   glycerophosphoethanolamine

k

:   exchange rate constant

HDL

:   high density lipoprotein

MRS

:   magnetic resonance spectroscopy

MUI

:   monounsaturation index

NADPH

:   nicotinamide adenine dinucleotide phosphate

NAFL

:   non‐alcoholic fatty liver

NAFLD

:   non‐alcoholic fatty liver disease

NASH

:   non‐alcoholic steatohepatitis

PCr

:   phosphocreatine

PDE

:   phosphodiester

PE

:   phosphoethanolamine

Pi

:   inorganic phosphate

PME

:   phosphomonoester

PNPLA3

:   patatin‐like phospholipase domain‐containing protein 3

PRESS

:   point resolved spectroscopy

PUFA

:   polyunsaturated fatty acid

PUI

:   polyunsaturation index

SI

:   saturation index

TM6SF2

:   transmembrane 6 superfamily 2

TP

:   total phosphorus

VOI

:   volume of interest

WHR

:   waist‐to‐hip ratio

Key pointsSaturation transfer including dynamic ATP flux is significant lower in NASH than NAFL.Higher ratios of PCr/TP and lower ratios of γATP/TP support data on apparent mitochondrial defects in NASH.Ultra‐high field MRS leads to shorter acquisition times and may therefore improve clinical applicability.Poly‐ to monounsaturated fatty acid indices were significantly higher in non‐obese (BMI\<30) than obese (BMI\>30) NAFLD patients.

1. INTRODUCTION {#liv13451-sec-0006}
===============

Non‐alcoholic fatty liver disease (NAFLD) has gradually become a wide spread disease affecting 40‐50% of the general population[1](#liv13451-bib-0001){ref-type="ref"} with serious hepatic outcomes including progression of non‐alcoholic steatohepatitis (NASH) to advanced fibrosis, cirrhosis and hepatocellular carcinoma (HCC). Liver biopsy still serves as reference standard in the diagnosis of NASH but is afflicted with major drawbacks such as feasibility, sampling error, intra‐ and interobserver variability and potential complications[2](#liv13451-bib-0002){ref-type="ref"} also lacking a functional in‐vivo assessment. Therefore, non‐invasive tools to monitor severity and progression of NAFLD are urgently needed.

Proton (^1^H)‐ and phosphorus (^31^P)‐MR spectroscopy (MRS) might allow a non‐invasive and real‐time detection of hepatic fat, cell membrane and energy metabolism.[3](#liv13451-bib-0003){ref-type="ref"}, [4](#liv13451-bib-0004){ref-type="ref"} 3 Tesla (T) ^1^H‐MRS is an effective tool to quantify liver steatosis[5](#liv13451-bib-0005){ref-type="ref"} and assess hepatic lipid composition.[6](#liv13451-bib-0006){ref-type="ref"} Data from ^31^P‐ and carbon‐13 (^13^C)‐MRS on hepatic energy[7](#liv13451-bib-0007){ref-type="ref"} and hepatic oxidative metabolism[8](#liv13451-bib-0008){ref-type="ref"} have already shown the utility evaluating the important role of the liver in the general regulation of glucose and lipid metabolism. However, most of the previously published studies on ^31^P‐MRS in NAFLD were limited to magnetic field strengths of 3 T or lower.[9](#liv13451-bib-0009){ref-type="ref"}, [10](#liv13451-bib-0010){ref-type="ref"} Higher magnetic field strengths result in an increased signal‐to‐noise ratio and higher spectral resolution, which is of particular importance for ^31^P‐MRS.[11](#liv13451-bib-0011){ref-type="ref"} We therefore explored the potential of high field 3 T ^1^H and ultra‐high field 7 T ^31^P‐MRS as a non‐invasive tool in NAFLD patients to obtain (i) novel mechanistic insights of lipid, cell membrane and energy homoeostasis in NAFLD and, (ii) novel imaging biomarkers of disease severity and progression including endoplasmic reticulum (ER) stress. In addition, we determined the rs738409 \[G\] polymorphism of patatin‐like phospholipase domain‐containing protein 3 (PNPLA3) and the transmembrane 6 superfamily 2 (TM6SF2) rs58542926 variants associated with liver steatosis, progression of liver disease and its complications,[12](#liv13451-bib-0012){ref-type="ref"}, [13](#liv13451-bib-0013){ref-type="ref"}, [14](#liv13451-bib-0014){ref-type="ref"} which has not been explored in the context of MRS so far.

2. PATIENTS AND METHODS {#liv13451-sec-0007}
=======================

2.1. Study design {#liv13451-sec-0008}
-----------------

This was a prospective, non‐randomized feasibility study of high field ^1^H‐ and ultra‐high field ^31^P‐MRS as a novel and non‐invasive tool for the assessment of NAFLD. It was approved by the ethics committees of the *Medical University Vienna* and the *Vienna General Hospital* (2011/129). All patients provided written informed consent.

2.2. Subjects {#liv13451-sec-0009}
-------------

Subjects scheduled for routine liver biopsy with suspected NAFLD were recruited from the NAFLD outpatient clinic of the Medical University Vienna (Figure [1](#liv13451-fig-0001){ref-type="fig"}). Histological assessment was performed by two board certified pathologists (JS, FW) unaware of the MRS data serving as reference standard for the diagnosis of NAFL, NASH, severity of inflammation and fibrosis (see below). Moreover, we collected comprehensive medical history and clinical data including physical examination, liver biochemistry, glycaemic parameters and lipid profiles (Table [1](#liv13451-tbl-0001){ref-type="table-wrap"}).

![Patient selection patients were invited to participate in this study if liver biopsy was planned in suspected non‐alcoholic fatty liver disease (NAFLD) patients and magnetic resonance eligibility was confirmed. After obtaining consent patients were further selected when liver biopsy showed NAFLD non‐alcoholic fatty liver or non‐alcoholic steatohepatitis as single diagnosis](LIV-37-1544-g001){#liv13451-fig-0001}

###### 

Baseline characteristics of the patient population

                                                                                                           NAFL (n=8)   NASH (n=22)
  -------------------------------------------------------------------------------------------------------- ------------ -------------------------------------------------------------------------------------------
  Male (%)                                                                                                 3 (38%)      15 (68%)
  Age[a](#liv13451-note-0003){ref-type="fn"} (years)                                                       48.0±9.6     48.0±12.5
  Diabetes                                                                                                 0 (0)        8 (36)[b](#liv13451-note-0004){ref-type="fn"} ^,^ [d](#liv13451-note-0006){ref-type="fn"}
  BMI[a](#liv13451-note-0003){ref-type="fn"}                                                               27.3±5.2     31.4±4.1[d](#liv13451-note-0006){ref-type="fn"}
  WHR[a](#liv13451-note-0003){ref-type="fn"}                                                               0.90±0.05    0.98±0.07[e](#liv13451-note-0007){ref-type="fn"}
  Non‐obese (BMI\<30)                                                                                      6 (75%)      10 (45%)
  PNPLA3                                                                                                                
  CC/GC                                                                                                    5/3          9/7
  GG                                                                                                       0            6[e](#liv13451-note-0007){ref-type="fn"}
  TM6SF2                                                                                                                
  CC                                                                                                       7            18
  CT                                                                                                       1            3
  TT                                                                                                       0            1
  AST[a](#liv13451-note-0003){ref-type="fn"} (IU/L)                                                        38.1±14.2    58.5±57.8
  ALT[a](#liv13451-note-0003){ref-type="fn"} (IU/L)                                                        63.8±28.0    80.4±48.4
  GGT[a](#liv13451-note-0003){ref-type="fn"} (IU/L)                                                        163±62       159±224
  HbA1c[a](#liv13451-note-0003){ref-type="fn"} (%)                                                         5.4±0.4      5.8±0.8
  HOMA‐IR[a](#liv13451-note-0003){ref-type="fn"}                                                           1.7±0.6      3.8±2.9
  Cholesterol[a](#liv13451-note-0003){ref-type="fn"} ^,^ [c](#liv13451-note-0005){ref-type="fn"} (mg/dL)   221±36       199±45
  HDL[a](#liv13451-note-0003){ref-type="fn"} (mg/dL)                                                       60±18        40±32
  LDL[a](#liv13451-note-0003){ref-type="fn"} (mg/dL)                                                       128±31       103±54
  Triglycerides[a](#liv13451-note-0003){ref-type="fn"} (mg/dL)                                             169±95       244±309

BMI, body mass index; NAFL, non‐alcoholic fatty liver; NASH, non‐alcoholic steatohepatitis; PNPLA3, patatin‐like phospholipase domain‐containing protein 3; TM6SF2, transmembrane 6 superfamily 2; WHR, waist‐to‐hip ratio.

Values given as mean±SD.

Six patients were on a stable dose of metformin and two on simple diabetic diet.

Two patients with NAFL and six with NASH were on statin therapy.

*P*\<.05.

*P*\<.01.

John Wiley & Sons, Ltd

2.3. Inclusion and exclusion criteria {#liv13451-sec-0010}
-------------------------------------

Patients had to be between 18 and 70 years old and scheduled for liver biopsy with suspected NAFLD. Exclusion criteria were as followed: (i) established chronic liver diseases other than NAFLD (ie, viral hepatitis, autoimmune liver disease, hereditary hemochromatosis, alpha‐1‐antitrypsin deficiency, Wilson′s disease, alcoholic liver disease and cholestatic liver diseases). Patients were excluded in case of: (ii) daily alcohol consumption \>30 g in males and \>20 g in females, (iii) age \<18 years, (iv) acute diseases within the last 2 weeks before the investigation, (v) severe or untreated heart, kidney, lung and blood disease (eg, heart failure NYHA III or IV, CKD stage \>2, COPD Gold \>2, any haematopoietic or lymphoid malignancy), (vi) current unstable thyroid disease, (vii) pregnancy, (viii) contraindications to MRS or liver biopsy.

2.4. Genetic testing {#liv13451-sec-0011}
--------------------

Single nucleotide polymorphisms rs738409 (PNPLA3) and rs58542926 (TM6SF2) were analyzed using the StepOnePlus Real Time PCR Systems (Applied Biosystems; Foster City, CA, USA) with a TaqMan SNP Genotyping Assay developed together with Applied Biosystems using published sequences from the NCBI Entrez SNP Database.

2.5. MR‐spectroscopy {#liv13451-sec-0012}
--------------------

MR spectroscopy was performed in fasting conditions, early in the morning within a 2‐hour time frame prior to liver biopsy.

### 2.5.1. ^1^H‐MRS {#liv13451-sec-0013}

Hepatic steatosis and hepatic lipid composition were measured using single voxel PRESS sequence (TE=30 ms, TR=2000 ms, VOI: 3×3×3 cm^3^, six averages within acquisition time of 16 seconds during breathold) at 3 T (Trio Tim; Siemens Healthcare, Erlangen, Germany) with the whole body RF coil for excitation and the combination of body‐matrix and spine coil, supplied by system manufacturer, for signal acquisition. Representative spectra and typical VOI position are depicted in Figure [2](#liv13451-fig-0002){ref-type="fig"} (panel A‐C). Spectra were analyzed with AMARES within jMRUI[15](#liv13451-bib-0015){ref-type="ref"} and fat total signal area (FTSA---equal to hepatic steatosis) was assessed as the ratio of lipid signals (0.9‐2.8 ppm) to the whole ^1^H MRS signal including that of water following appropriate T~1~ and T~2~ correction.

![Magnetic resonance spectroscopy (MRS) procedure and representative ^1^H and ^31^P spectra of patients with non‐alcoholic fatty liver disease (NAFL) and non‐alcoholic steatohepatitis (NASH). The Volume of Interest for ^1^H‐MRS was placed in the right lobe of the liver (A). The different amounts of hepatic fat are illustrated by ^1^H spectra from patient with NAFL and NASH (B, C respectively). The 2D chemical shift imaging (CSI) slice for ^31^P‐MRS was placed parallel to the RF surface coil carefully avoiding superficial skeletal muscle tissue (D). Signals from shaded voxels (4×4) were selected for processing and further analysis. The ^31^P spectra from patients with NAFL (no/mild fibrosis) and NASH (advanced fibrosis) are depicted in E and F respectively. For illustration purposes, the ^31^P spectra were filtered with 10 Hz Lorentzian filter. All amplitudes of the signals are in arbitrary units](LIV-37-1544-g002){#liv13451-fig-0002}

Lipid composition was assessed as lipid saturation (SI), unsaturation (UI), polyunsaturation (PUI) and monounsaturation (MUI) indices calculated as published before.[6](#liv13451-bib-0006){ref-type="ref"}

### 2.5.2. ^31^P‐MRS {#liv13451-sec-0014}

For ^31^P‐MRS, the patients were placed in the right lateral position within a 7 T whole body MR system (Magnetom, Siemens Healthcare). Two dimensional ^31^P‐MR chemical shift imaging (CSI) sequence (TE=1 ms, TR=1800 ms, 12×12 matrix interpolated to 16×16, FOV: 20×20 cm, four averages, acquisition time of approx. Ten minutes[16](#liv13451-bib-0016){ref-type="ref"} was applied on the 3 cm thick sagittal slice prescribed well in the liver parenchyma parallel to the RF surface coil (^1^H/^31^P, 10 cm in diameter, Rapid Biomedical GmbH, Rimpar, Germany). Spectroscopic field of view was carefully chosen to avoid any contamination from a superficial skeletal muscle tissue (Figure [2](#liv13451-fig-0002){ref-type="fig"}D‐F). From the ^31^P MR signal, the amplitudes of phosphomonoester (PME) \[phosphoethanolamine (PE)+phosphocholine\], phosphodiester (PDE) \[glycerophosphocholine (GPC)+glycerophosphoethanolamine\], uridine‐diphosphoglucose, nicotine adenine dinucleotide phosphate (NADPH), inorganic phosphate (Pi), phosphatidylcholine, α‐ and γ‐adenosine triphosphate (ATP), phosphocreatine (PCr) and total phosphorus (TP) were determined as described before.[17](#liv13451-bib-0017){ref-type="ref"}, [18](#liv13451-bib-0018){ref-type="ref"} VOI of 4×4 voxels with a sufficient signal‐to‐noise and no contamination from the skeletal muscle was chosen for further signal analysis. Individual phase and frequency shift correction was performed prior to a signal deconvolution with AMARES within jMRUI. Metabolite levels are expressed as ratio to TP or as ratio to γ‐ATP signal following appropriate T~1~ correction. At the end of measurement protocol, saturation transfer experiment was performed at the sagittal slab identical to the FOV of 2D CSI sequence. The chemical exchange rate constant *k* of the Pi‐to‐ATP reaction and the unidirectional forward exchange flux (*F* ~ATP~) were calculated as published before.[19](#liv13451-bib-0019){ref-type="ref"}

2.6. Liver biopsy and histology {#liv13451-sec-0015}
-------------------------------

Ultrasound assisted percutaneous liver biopsy was performed under local anaesthesia according to standard procedures[20](#liv13451-bib-0020){ref-type="ref"} and in fasting condition. For histological analysis samples were routinely processed (formalin‐fixed and paraffin‐embedded), stained with haematoxylin/eosin and chrome aniline blue for assessment of fibrosis, steatosis and inflammation as well as with Prussian blue for iron.

Steatosis, ballooning, lobular inflammation and fibrosis were staged according to the *NASH Clinical Research Network Scoring System* definitions[21](#liv13451-bib-0021){ref-type="ref"}: steatosis involving \<5% of cells (S0, no steatosis), 5%‐33% (S1, mild), \>33%‐66% (S2, moderate) and \>66% (S3, severe) of hepatocytes; ballooning was graded as none (0), few balloon cells (1) and many cells/prominent ballooning (2); lobular inflammation was graded as no foci (0, none), \<2 foci (1, mild), 2‐4 foci (2, moderate) and \>4 foci per 200× field (3, marked); fibrosis was staged as none (F0), perisinusoidal or periportal (F1), perisinusoidal and portal/periportal (F2), bridging fibrosis (F3) and cirrhosis (F4). The diagnosis of *non‐alcoholic fatty liver* (NAFL) was made if steatosis was ≥5% and either ballooning *or* lobular inflammation or both were absent. The diagnosis of NASH was made given that: (i) steatosis was ≥5%, (ii) ballooning *and* lobular inflammation were present.[22](#liv13451-bib-0022){ref-type="ref"} Clinical differentiation was made for fibrosis stages 0‐2 as no/mild fibrosis and for stages 3 and 4 as advanced fibrosis.

2.7. Statistical analysis {#liv13451-sec-0016}
-------------------------

Statistical analysis was performed with commercially available software ([spss]{.smallcaps} Version 23; IBM Corp., Chicago, IL, USA). Continuous variables were expressed as mean ± standard deviation while categorical variables as absolute (n) with relative frequencies (%). Comparison of continuous variables was calculated using the Student\'s *t*‐test. Pearson\'s product moment correlation was used to calculate linear relationships between variables. Categorical variables were compared using the analysis of variance (ANOVA). Binary logistic regression was used where appropriate. Factors showing significant association in univariate analysis were also included into a multivariate model. Multivariate analysis was performed for F~ATP~ and *k* including BMI, waist‐to‐hip ratio (WHR), hepatic steatosis and the presence of diabetes for the discrimination of NAFL and NASH. All tests were two‐sided with a *P*‐value below .05 as level of significance.

3. RESULTS {#liv13451-sec-0017}
==========

3.1. Patients' characteristics {#liv13451-sec-0018}
------------------------------

Thirty patients with NAFLD undergoing liver biopsy between 2010 to 2013 were included in this study (Figure [1](#liv13451-fig-0001){ref-type="fig"}), eight of them with NAFL and 22 with NASH (clinical characteristics see Table [1](#liv13451-tbl-0001){ref-type="table-wrap"}). No difference between sex and age was observed between both groups. NASH patients had a significantly higher BMI and WHR. Non‐obese (BMI\<30) and obese (BMI\>30) NAFLD patients were equally distributed with no significant difference between NAFL and NASH. In this cohort, only patients with NASH had diabetes. Concomitant anti‐diabetic therapy included metformin in six patients and diabetic diet only in two patients. Eight patients had statin therapy without statistical differences between the two groups. In addition, there was no significant difference in serum cholesterol or HOMA index. The contribution of the PNPLA3 rs738409 polymorphism was only significantly different between NASH and NAFL for genotype GG (148M/M) (*P*=.003), which was not significant for TM6SF2 variants. Histology data is shown in Table [2](#liv13451-tbl-0002){ref-type="table-wrap"}.

###### 

Histological characteristics of the subject cohort

                                                                NAFL (n=8) [a](#liv13451-note-0010){ref-type="fn"}   NASH (n=22)
  ------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------
  Steatosis[b](#liv13451-note-0011){ref-type="fn"} (%)          15±10                                                65±24[d](#liv13451-note-0013){ref-type="fn"}
  Ballooning[b](#liv13451-note-0011){ref-type="fn"}             0.8±0.7                                              1.3±0.6[c](#liv13451-note-0012){ref-type="fn"}
  Lobular inflammation[a](#liv13451-note-0010){ref-type="fn"}   0.60±0.52                                            1.40±0.50[d](#liv13451-note-0013){ref-type="fn"}
  Fibrosis[a](#liv13451-note-0010){ref-type="fn"} (Kleiner)     0.5±0.5                                              1.8±1.2[d](#liv13451-note-0013){ref-type="fn"}
  NAS[a](#liv13451-note-0010){ref-type="fn"}                    2.25±1.10                                            5.30±1.40[d](#liv13451-note-0013){ref-type="fn"}
  Fibrosis grade 3/4 (%)                                        0 (0)                                                6 (27)
  Cirrhosis (%)                                                 0 (0)                                                3 (14)

NAFL, non‐alcoholic fatty liver; NASH, non‐alcoholic steatohepatitis.

Patients diagnosed with non‐alcoholic steatohepatitis NASH in histology needed at least one point for ballooning and lobular inflammation, respectively, with grade 1 or higher in hepatic steatosis.[22](#liv13451-bib-0022){ref-type="ref"}

Including four patients with possible borderline NASH (= grade 1‐2 ballooning without lobular inflammation or grade 1‐2 lobular inflammation without ballooning).

Values given as mean ± standard deviation.

*P*\<.05.

*P*\<.01.

John Wiley & Sons, Ltd

3.2. ^1^H MRS {#liv13451-sec-0019}
-------------

Steatosis as calculated from ^1^H‐MRS at 3 T highly correlated with histological steatosis (*r*=.716, *P*\<.001) (Figure [3](#liv13451-fig-0003){ref-type="fig"}) and lobular inflammation (*r*=.420, *P*=.021). Steatosis in MRS also correlated with BMI (*r*=.506, *P*=.004), serum triglycerides (*r*=.444, *P*=.014) but not cholesterol or diabetes. Serum high‐density lipoprotein (HDL) levels highly decreased with increasing degree of steatosis in MRS (*r*=−0.550, *P*=.002). Notably, we observed no differences between NAFL and NASH in lipid composition measured as lipid saturation (SI), polyunsaturation (PUI) and monounsaturation (MUI) indices, however, PUI to MUI ratios were significantly higher in non‐obese (BMI\<30) than obese (BMI\>30) individuals (*P*=.025). ^1^H‐MRS showed higher PUI in PNPLA3 genotype GG (*r*=.423; *P*=.02). Importantly, NASH patients showed significantly higher degrees of steatosis on MRS cross‐validated by liver histology compared to NAFL (*P*\<.001; Figure [3](#liv13451-fig-0003){ref-type="fig"}). There was no correlation between genotype GG and steatosis. However, steatosis negatively correlated with genotype CC (*P*=.023). No correlation was found within TM6SF2 variants.

![Hepatic fat fraction in non‐alcoholic fatty liver disease (NAFL) and non‐alcoholic steatohepatitis (NASH) assessed with ^1^H‐MRS and liver histology. (A) High correlation of lipid content on liver histology as gold standard with 3 T ^1^H‐MRS (*r*=.716, *P*\<.001). NASH patients show a higher hepatic fat fraction on (B) 3 T ^1^H‐MRS (*P*\<.001), which was also confirmed by (C) histology (*P*\<.001)](LIV-37-1544-g003){#liv13451-fig-0003}

3.3. ^31^P MRS {#liv13451-sec-0020}
--------------

### 3.3.1. Phosphomonoesters and phosphodiesters {#liv13451-sec-0021}

PE/(PME+PDE) (*P*=.04), PE/γ‐ATP (*P*=.002) and PE/TP (*P*=.015) ratios as markers of cell membrane turnover were lower in patients with no/mild fibrosis (F0‐2) than advanced fibrosis F3‐4. This was also observed for PME/γ‐ATP ratios (*P*=.013). Inversely, GPC/(PME+PDE) ratios (*P*=.05) as cell membrane breakdown products were higher in no‐to‐mild fibrosis compared to advanced fibrosis (Figure [4](#liv13451-fig-0004){ref-type="fig"}). There was no correlation with lobular inflammation but slightly higher PME/TP ratios in grade 2 ballooning than in grade 1 (grade 2\>1; *P*=.015) without difference to grade 0 (grade 1\>0; *P*=.28).

![^31^P‐MRS: Phosphomonoesters and phosphodiesters uncover alterations in cell membrane metabolism in non‐alcoholic fatty liver disease (NAFLD). Phosphomonoesters like phosphoethanolamine (PE) were significantly higher in advanced fibrosis than no‐to‐mild fibrosis: (A) PE/phosphomonoester (PME)+phosphodiester(PDE) (*P*=.04), (B) PE/γ‐adenosine triphosphate (ATP) (*P*=.002) and (C) PME/γ‐ATP (*P*=.013). (D) This was reversed for phosphodiesters like glycerophosphocholine (GPC)/(PME+PDE) (*P*=.05). ^31^P‐MRS shows alterations in cell membrane metabolism in advanced NAFLD with higher degree of fibrosis](LIV-37-1544-g004){#liv13451-fig-0004}

### 3.3.2. ATP, inorganic phosphate, phosphocreatine and NADPH {#liv13451-sec-0022}

γ‐ATP/TP (*P*=.049) ratio as marker of hepatic energy metabolism decreased from F0‐2 to F3‐4. PCr/γ‐ATP (*P*=.002) and PCr/TP (*P*=.014) ratios conversely increased in patients with advanced fibrosis after multivariate analysis for the presence of diabetes. NADPH/(PME+PDE) (*P*=.048), NADPH/γ‐ATP (*P*=.028) and NADPH/TP (*P*=.026) ratios were higher in grade 0 to 2 ballooning rising from few (grade 1) to many ballooned cells (grade 2) (*P*=.05) in NADPH/TP (Figure [5](#liv13451-fig-0005){ref-type="fig"}). There was no significant difference between diabetic and non‐diabetic individuals in ATP, PCr or NADPH. Contamination of hepatic ^31^P‐MRS signal by the signal from superficial skeletal muscle was minimized by the choice of MRSI field of view, prescribed as sagittal slice parallel to the surface coil, placed well within liver parenchyma (Figure [2](#liv13451-fig-0002){ref-type="fig"}D) and acquisition frequency centred to PCr resonance position, leading to no chemical shift displacement artefact. Subsequently, VOI was carefully selected during signal processing, ensuring that our spectra were not affected by the signals from skeletal muscle.

![^31^P‐MRS: adenosine triphosphate (ATP), inorganic phosphate, phosphocreatine and nicotinamide adenine dinucleotide phosphate (NADPH) reflecting altered energy metabolism in non‐alcoholic fatty liver disease (NAFLD). ^31^P‐MRS data show an altered hepatic energy metabolism in higher grades of fibrosis in NAFLD patients. (A) Advanced fibrosis showed lower levels of γ‐adenosine triphosphate (ATP)/total phosphorus (TP) (*P*=.049). (B) Conversely phosphocreatine (PCr)/TP increased in advanced fibrosis (*P*=.014). (C) NADPH/TP ratios increased with higher grades of ballooning (no (0) vs many ballooned cells (2), *P*=.028; few (1) vs many ballooned cells (2), *P*=.05). Choice of spectroscopic field of view, which can be described as sagittal slab parallel to the surface coil, placed well within liver parenchyma (Figure [2](#liv13451-fig-0002){ref-type="fig"}D), acquisition frequency centred to PCr resonance position, leading to no chemical shift displacement artefact, and careful volume of interest (VOI) selection during signal processing, all supports the valid assumption, that our spectra are not contaminated by the signals from skeletal muscle](LIV-37-1544-g005){#liv13451-fig-0005}

### 3.3.3. Saturation transfer: forward exchange flux and exchange rate constant {#liv13451-sec-0023}

Mean *k* values assessing mitochondrial function were significantly lower in patients with NASH (0.20±0.07/seconds) than in those with NAFL (0.30±0.07/seconds; *P*=.003). NASH patients had also lower estimated *F* ~ATP~ values (0.21±0.08 mM/seconds) than NAFL patients (0.38±0.08 mM/seconds; *P*\<.001) (Figure [6](#liv13451-fig-0006){ref-type="fig"}) and were both still significant after multivariate analysis for BMI, the presence of diabetes and adjusting for steatosis. There was no correlation with ballooning in histology but a strong correlation of lobular inflammation to both *k* values (*P*=.007) and *F* ~ATP~ values (*P*\<.001). In addition, a minor correlation was found for *F* ~ATP~ and steatosis measured by histology (*P*=.03) and 3 T ^1^H‐MRS (*P*=.021).

![Saturation transfer ^31^P‐MRS: Higher adenosine triphosphate (ATP) fluxes in non‐alcoholic fatty liver disease (NAFLD) than non‐alcoholic steatohepatitis (NASH). (A) Forward exchange flux (*F*~ATP~) was lower in patients with NASH (0.21±0.08 mM/s) than with non‐alcoholic fatty liver (NAFL) (0.38±0.08 mM/s) consistent with abnormal mitochondrial function (*r*=−.679; *P*\<.001). (B) In addition a minor correlation was also found for *F*~ATP~ and steatosis in 3‐T ^1^H‐MRS (*r*=−.443; *P*=.021)](LIV-37-1544-g006){#liv13451-fig-0006}

4. DISCUSSION {#liv13451-sec-0024}
=============

To our best knowledge, this is the first prospective clinical trial evaluating overall hepatic (3 T) ^1^H‐ and (7 T) ^31^P‐MR spectroscopy (MRS) profiles including dynamic saturation transfer technique in biopsy proven NAFLD patients uncovering important metabolic differences between NAFL and NASH.

Hepatic steatosis as determined by 3 T ^1^H‐MRS highly correlated with histological steatosis. As ^1^H‐MRS quantifies the relative amount of fat in the entire region of interest and histology states the fraction of steatotic liver cells a direct comparison regarding quantification of fat might not be advantageous. However, using a linear regression model as described before[23](#liv13451-bib-0023){ref-type="ref"} an approximation to histology is possible even though not implicitly required considering the well known shortcomings of liver histology regarding fat quantification. In this cohort, hepatic fat in ^1^H‐MRS and histology was higher in NASH patients than in patients with NAFL. In addition, lobular inflammation correlated with hepatic fat in MRS. This supports recent data from the *NASH Clinical Research Network* [24](#liv13451-bib-0024){ref-type="ref"} showing significant correlations between increasing levels of steatosis and diagnosis of NASH.

Lipid saturation with higher prevalence of potentially more toxic unsaturated fatty acids may be a critical determinant of lipotoxicity.[25](#liv13451-bib-0025){ref-type="ref"} We therefore used ^1^H‐MRS to assess lipid saturation profiles (ie, SI, UI, MUI, PUI) but observed no differences between NAFL and NASH, non‐diabetics and diabetics or different stages of fibrosis. Interestingly, hepatic PUI to MUI ratios were significantly higher in non‐obese (BMI\<30) than obese (BMI\>30) NAFLD patients. Notably, our results are in line with hepatic lipidomic analysis of NAFLD showing no difference between NAFL and NASH.[26](#liv13451-bib-0026){ref-type="ref"} In addition, hepatic PUI was increased in homozygous carriers of the PNPLA3 I148M variant (G/G), which may be considered as a specific subtype of NASH[27](#liv13451-bib-0027){ref-type="ref"} but not in any TM6SF2 variant.

NAFLD/NASH is a condition possibly characterized by ER stress.[28](#liv13451-bib-0028){ref-type="ref"} We tested the hypotheses that ultra‐high field ^31^P‐MRS may uncover alterations in phospholipid metabolites such as PME and PDE previously prescribed as markers of hepatic endoplasmic stress.[29](#liv13451-bib-0029){ref-type="ref"} However, we did not observe any differences in PMEs and PDEs possibly due to a higher differentiation of the PME and PDE signals at 7 T. Levels of PE were lower in no‐to‐mild than in advanced fibrosis, which was also reflected by PME/γ‐ATP ratios. Inversely, GPC/(PME+PDE) ratios were higher in advanced fibrosis supporting former data.[30](#liv13451-bib-0030){ref-type="ref"} Our results reflect alterations in cell membrane metabolism in advanced NASH as described in diffuse liver disease,[31](#liv13451-bib-0031){ref-type="ref"} fibrosis and cirrhosis.[32](#liv13451-bib-0032){ref-type="ref"}

In this study, we uncovered decreased ratios of γ‐ATP/TP in advanced fibrosis indicating a disturbed energy metabolism in advanced steatohepatitis. Decreasing concentrations of hepatic ATP were also shown in patients with type 2 diabetes [33](#liv13451-bib-0033){ref-type="ref"} which could not be shown in our cohort. Nevertheless, multivariate analysis was performed adjusting for possible effects of diabetes, BMI and WHR on hepatic energy metabolism, not changing the original findings.

Previous studies uncovered hepatic mitochondrial structural defects and functional mitochondrial abnormalities in NASH.[17](#liv13451-bib-0017){ref-type="ref"}, [34](#liv13451-bib-0034){ref-type="ref"} This may indicate that changes in hepatic energy homoeostasis and increased oxidative stress in NASH could promote cell injury and inflammation. In this study, PCr/γ‐ATP and PCr/TP ratios increase with advanced fibrosis supporting the concept of dysfunctional mitochondria in advanced NASH.[10](#liv13451-bib-0010){ref-type="ref"}, [35](#liv13451-bib-0035){ref-type="ref"} To exclude contamination of hepatic ^31^P‐MRSI data by signals from skeletal muscle, we carefully analyzed our acquisition scheme and compared presented data post hoc with data from healthy volunteers partially published before.[18](#liv13451-bib-0018){ref-type="ref"} The retrospective analysis of these identically acquired spectra [18](#liv13451-bib-0018){ref-type="ref"} from young healthy volunteers (n=9) yielded mean PCr/TP signal of 0.010±0.007 similar to data from patients with no or mild fibrosis from this study. Collectively, this strongly supports that the statistical increase in PCr/TP signal from liver of patients with advanced fibrosis represents real presence of PCr in the measured volume. So far, no other study on MR spectroscopy in NAFLD or diabetes has shown the presence of PCr signals, which might be explained by the higher resolution of ultra‐high field MR at 7 T. Therefore, interpretation of these findings should be done with caution, until confirmed in larger studies.

Although PCr is usually not present in normal hepatocytes and healthy liver,[36](#liv13451-bib-0036){ref-type="ref"} creatine kinase (CK) activities in endothelial cells, Kupffer and Ito cells could be shown in several in vivo and in vitro experimental models.[37](#liv13451-bib-0037){ref-type="ref"} Our results might be therefore explained by a compensatory up‐regulation of CK expression in advanced NASH with more advanced fibrosis due to a dysfunctional hepatic microvasculature [38](#liv13451-bib-0038){ref-type="ref"} and hypoxia.[39](#liv13451-bib-0039){ref-type="ref"} NADPH additionally increased with higher grades of hepatocellular ballooning possibly reflecting higher oxidative activity during inflammation[40](#liv13451-bib-0040){ref-type="ref"} formerly shown in NASH.[30](#liv13451-bib-0030){ref-type="ref"}

Finally, we used the saturation transfer technique to assess dynamic Pi‐to‐ATP exchange parameters in NAFL and NASH, which was already used to monitor changes in the Pi‐to~‐~ATP flux reflecting alterations in the mitochondrial metabolism in the human muscle[41](#liv13451-bib-0041){ref-type="ref"} not shown for liver tissue so far. The exchange rate constant *k* and the unidirectional forward exchange flux *F* ~ATP~ were significantly lower in patients with NASH than with NAFL even after correction for the effects of diabetes, BMI and steatosis emphasizing our pilot study results[19](#liv13451-bib-0019){ref-type="ref"} in showing a disturbed energy metabolism in NASH. Both, increased fatty acid β‐oxidation and hepatic oxidative stress are common in NAFLD.[34](#liv13451-bib-0034){ref-type="ref"} However, a loss of adaptive mechanisms in mitochondrial function and mitochondrial structural defects has only been associated with NASH[7](#liv13451-bib-0007){ref-type="ref"}, [10](#liv13451-bib-0010){ref-type="ref"}, [34](#liv13451-bib-0034){ref-type="ref"} and progressive impairment of the mitochondrial respiratory capacity may play a pivotal role in the progression of NASH.[42](#liv13451-bib-0042){ref-type="ref"} To illustrate the potential application of dynamic saturation transfer, we performed a small pilot case series of three patients who underwent ^1^H‐ and ^31^P‐MRS 12 months after a dietary intervention (Figure [S1](#liv13451-sup-0001){ref-type="supplementary-material"}) showing regenerating Pi‐to‐ATP exchange parameters when hepatic steatosis improved (n=2) while revealing further impairment of Pi‐to‐ATP exchange parameters in case (n=1) of increasing hepatic steatosis, which at this point is rather preliminary and speculative until more extensively investigated.

As limitations of our study we have to acknowledge that the sample volume of liver biopsies and the region of interest measured by MRS are different, which is due to technique limitations in liver biopsy. This study was planned as a pilot study to evaluate the feasibility of extended high and ultra‐high field ^1^H‐ and ^31^P‐MRS profiles in NAFLD patients and therefore the sample size is relatively small. We are aware, that the best possible internal reference and the measure of energy metabolism would be the β‐ATP resonance, but limited spectral bandwidth of slice selective radio frequency pulses does not allow for effective excitation of β‐ATP signal at 7 Tesla. For this technical reason, γ‐ATP was chosen as the surrogate marker of energy metabolism. Furthermore, there is a possible selection bias towards patients with more advanced disease due to the requirements for routine liver biopsy indication. Conversely, the subjects characterized by NAFL were clustered in a rather low range of the steatosis scale. However, a major strength of this study is the exact timeline with short intervals and constant fasting conditions at which MRS and liver biopsy were conducted.

In conclusion, 3 T ^1^H‐ and 7 T ^31^P‐MRS are highly accurate and fast non‐invasive methods, generating broad in vivo lipid, cell membrane and energy metabolism profiles of the human liver. Ultra‐high field MRS at 7 Tesla with higher spectral resolution and increased signal‐to‐noise ratios leads to shorter acquisition times and may therefore improve clinical applicability in a tertiary (research) setting. Dynamic saturation transfer including ATP flux shows significant differences in hepatic energy metabolism between NAFL and NASH with compensatory increasing ratios of phosphocreatine supporting data on apparent mitochondrial structure defects in NASH. 3 T ^1^H‐ and 7 T ^31^P‐MRS may allow non‐invasive metabolic profiling assisting further mechanistic and therapeutic studies of NAFLD/NASH.
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